Literature DB >> 12212638

Brain mechanisms of visual encoding and working memory in psychometrically identified schizotypal individuals and after acute administration of haloperidol.

Bruno Kopp1, Monika Wolff, Claudia Hruska, Friedel M Reischies.   

Abstract

A probabilistic association task that manipulated the necessity to temporarily store information was combined with the recording of event-related potentials. In Experiment 1, scores obtained from a positive schizotypy scale were used to categorize participants as either low or high schizotypal individuals. Low, but not high, schizotypal individuals displayed evidence for selective associative learning in the working memory dependent ("trace") version of the task. The amplitudes of the occipito-temporal N150 were attenuated in high schizotypal individuals. In Experiment 2, the intravenous administration of a single dose of haloperidol (0.04 mg/kg), but not of a placebo, strengthened the selectivity of associative learning in the trace version of the task. The amplitudes of the occipito-temporal N150 were augmented by haloperidol. Psychometrically identified schizotypal individuals and normal individuals under mild stress demonstrated defective prioritization of information in working memory and deficient visual encoding. These neurocognitive effects of schizotypy and stress seem to be mediated by the D2 family of dopamine receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12212638     DOI: 10.1017.S0048577202001026

Source DB:  PubMed          Journal:  Psychophysiology        ISSN: 0048-5772            Impact factor:   4.016


  2 in total

1.  Levodopa reverses gait asymmetries related to anhedonia and magical ideation.

Authors:  Christine Mohr; Theodor Landis; H Stefan Bracha; Marc Fathi; Peter Brugger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 2.  An Overview of the Association between Schizotypy and Dopamine.

Authors:  Christine Mohr; Ulrich Ettinger
Journal:  Front Psychiatry       Date:  2014-12-19       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.